Plasminogen Activator Type 1 (Hf Epitope) antibody

Catalog No. ABIN2192039

Product Details

Target: Plasminogen Activator Type 1

Binding Specificity: Hf Epitope

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: Un-conjugated

Application: Functional Studies (Func), Western Blotting (WB)

Cross-Reactivity (Details): Cross reactivity: Mouse, rat : Yes

Sterility: 0.2 μm filtered

Clone: MA-33H1F7

Isotype: IgG1

Application Details

Application Notes: For Western blotting, dilutions to be used depend on detection system applied. It is recommended that users test the reagent and determine their own optimal dilutions. The typical starting working dilution is 1:50. For functional studies, dilutions have to be optimized in user's experimental setting.

Restrictions: For Research Use only

Handling

Buffer: PBS, containing 0.1 % bovine serum albumin.

Storage: 4 °C

Storage Comment: Product should be stored at 4 °C. Under recommended storage conditions, product is stable for at least one year. The exact expiry date is indicated on the label.

References

Komissarov, Andreasen, Declerck, Kamikubo, Zhou, Gruber: "Redirection of the reaction between activated protein C and a serpin to the substrate pathway." in: Thrombosis research, Vol. 122, Issue 3, pp. 397-404, (2008) (PubMed).

Rupin, Martin, Vallez, Bonhomme, Verbeuren: "Inactivation of plasminogen activator inhibitor-1 accelerates thrombolysis of a platelet-rich thrombus in rat mesenteric arterioles." in: Thrombosis and haemostasis, Vol. 86, Issue 6, pp. 1528-31, (2002) (PubMed).

Sironi, Calvio, Arnaboldi, Corsini, Parolari, de Gasparo, Tremoli, Mussoni: "Effect of valsartan on angiotensin II-induced plasminogen activator inhibitor-1 biosynthesis in arterial smooth muscle cells." in: Hypertension, Vol. 37, Issue 3, pp. 961-6, (2001) (PubMed).

Debrock, Declerck: "Neutralization of plasminogen activator inhibitor-1 inhibitory properties: identification of two different mechanisms." in: Biochimica et biophysica acta, Vol. 1337, Issue 2, pp. 257-66, (1997) (PubMed).

Target Details

Target: Plasminogen Activator Type 1

Background: Plasminogen activator inhibitor type-1 (PAI-1), a member of the serine protease inhibitor (serpin) superfamily, is an important protein in the regulation of fibrinolysis. PAI-1 is unique among the serpins because of its functional and conformational flexibility. PAI-1 is the most important physiological inhibitor of both tissue-type plasminogen activator (t-PA) and urokinase-type plasminogen activator (u- PA). Increased PAI-1 levels are associated with thrombotic events and is an established risk factor for cardiovascular diseases. The active conformation PAI-1 inhibits its target proteinases by the formation of a stable, inactive complex. Although PAI-1 is synthesized as an active molecule, it converts spontaneously to an inactive, latent form that can be partially reactivated by denaturing agents. In addition, a third conformation reacting as a non-inhibitory substrate towards various target proteinases has been identified. The epitope of monoclonal antibody MA-33H1F7 is predominantly composed of three residues 154 130 131 (Lys /Glu /Arg ), positioned virtually linearly in the three-dimensional structure. The epitope of the antibody does not cover the complete alpha-helix F and turn connecting alpha-helix F and beta-strand s3A, but is restricted to the hinge region between alpha-helix F and the main part of the PAI-1 Molecule. The monoclonal antibody MA-33H1F7 is a 'switching' antibody, capable of inducing a non-inhibitory substrate form of PAI-1. It was shown to inhibit PAI-1 in a dose dependent manner. Aliases PAI-1, endothelial plasminogen activator inhibitor, serpin E1 Immunogen Human PAI-1/t-PA complex